Vitamin D deficiency as a sign of severity in bronchiectasis

Posted on by Muthanna Medical Journal

Research article

Volume 11, Issue 2,  2024.  Page 124-134    10.52113/1/1/2024-2-134

Authors
Mustafa Eskander Salman *1, Mohammed Waheeb Al-Obaidy 2    

*Correspondence author: mustafaeskander85@gmail.com

*1 Baghdad teaching hospital, Baghdad, Iraq.
2 College of Medicine, University of Baghdad, Baghdad, Iraq
 Received 19 July 2024; revised 27 August 2024; accepted 22 September 2024, available online 16 October 2024.
Copyright © 2024 Salman, et al. This is article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Abstract

Bronchiectasis is a chronic heterogeneous lung disease with poorly understood pathogenic processes and variable contributing factors. The aim of this study is to assess the prevalence and the impact of vitamin D deficiency in bronchiectasis patients. A cross-sectional study of 40 Baghdad teaching hospital respiratory diseases consultant outpatient clinic patients with verified bronchiectasis was undertaken between 2022 and 2023. 40 healthy, demographically matched controls were also studied. A detailed history, comprehensive physical examination with respiratory emphasis, and vitamin D level evaluation were done. Vitamin D levels were categorized as deficient (< 20 ng/ml), insufficiency (20–29.9 ng/ml), and adequate (≥ 30 ng/ml). Patients were categorized as frequent exacerbates (≥3 times/year) or non-frequent exacerbates (<3 times/year). Symptom intensity was further divided into mild, moderate, and severe. We studied 40 bronchiectasis patients, 21 of them were male and 7 had comorbidities. The mean age, BMI, ESR, and CRP for included patients were 39 years, 23.945 kg/m2, 9.65 ml/hr, and 0.234 mg/dL. Group vitamin levels averaged 19.68 ng/ml. Average annual exacerbation, BSI, Bhalla, and FEV1 scores were 1.95, 6.325, 14.275, and 85.8%. Bronchiectasis patients and healthy controls had similar demographic and clinical features except for vitamin D and CRP. Exacerbation number, BSI score, Bhalla score, and FEV1 correlated with vitamin D but not ESR or CRP. In conclusion, Vitamin D insufficiency is common in bronchiectasis patients and healthy people and is linked to poor symptom severity, radiological abnormalities, and lung function.

Keywords: Bronchiectasis, Vitamin D, Exacerbation, severity, Deficiency

References

  1. Ho T, Cusack RP, Chaudhary N, et al. Under- and over-diagnosis of COPD: a global perspective. Breathe (Sheff). 2019 Mar;15(1):24-35.
  2. Ferri S, Crimi C, Heffler E, et al. Vitamin D and disease severity in bronchiectasis. Respir Med. 2019 Mar;148:1-5.
  3. Guan WJ, Han XR, de la Rosa-Carrillo D, et al. The significant global economic burden of bronchiectasis: a pending matter. Eur Respir J. 2019 Feb;53(2).
  4. Keir HR, Chalmers JD. Pathophysiology of Bronchiectasis. Semin Respir Crit Care Med. 2021;42(4):499-512. doi:10.1055/s-0041-1730891.
  5. Moustaki M, Loukou I, Priftis KN, et al. Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis. World J Clin Pediatr. 2017 Aug 8;6(3):132-142. doi: 10.5409/wjcp.v6.i3.132. PMID: 28828295; PMCID: PMC5547424.
  6. Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonization and disease severity in bronchiectasis. Thorax, 2013, 68:39–47 [PMID: 23076388]. https://doi.org/10.1136/thoraxjnl-2012-202125.
  7. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet 2018;392(10150):880–890.
  8. Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016;47 (01):186–193.
  9. Bird K, Memon J. Bronchiectasis. [Updated 2023 May 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430810/.
  10. Macfarlane L, Kumar K, Scoones T, et al. Diagnosis and management of non-cystic fibrosis bronchiectasis. Clin Med (Lond). 2021;21(6):e571-e577. doi:10.7861/clinmed.2021-0651.
  11. Schäfer, J., Griese, M., Chandrasekaran, R. et al. Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. BMC Pulm Med 18, 79 (2018). https://doi.org/10.1186/s12890-018-0630-8.
  12. Aksamit TR, O’Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest. 2017;151(5):982–992.
  13. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446-1462. doi:10.1183/09031936.00119114.
  14. Maselli DJ, Keyt H, Restrepo MI. Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int J Mol Sci. 2017;18(5):1062. Published 2017 May 16. doi:10.3390/ijms18051062.
  15. Hnin K, Nguyen C, Carson KV, et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev. 2015;2015(8):CD001392. Published 2015 Aug 13. doi:10.1002/14651858.CD001392.pub3.
  16. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
  17. Powner J, Nesmith A, Kirkpatrick DP, et al. Employment of an algorithm of care including chest physiotherapy results in reduced hospitalizations and stability of lung function in bronchiectasis. BMC Pulm Med. 2019;19(1):82.
  18. Chalmers JD, Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020;383(22):2127–2137.
  19. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-585. doi:10.1164/rccm.201309-1575OC.
  20. De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018;51(1):1702052.
  21. Simoneau T, Bazzaz O, Sawicki GS, et al. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc, 2014, 11:205–210 [PMID:24423241]. https://doi.org/10.1513/annalsats.201306-171bc.
  22. Martinez-Garcia MÁ, Athanazio R, Gramblicka G, et al. (2019) Prognostic value of frequent exacerbations in bronchiectasis: the relationship with disease severity. Arch Bronconeumol. 55:81–87 Google Scholar 1700629.
  23. S. Salim, K., Ghassan, et  al. Prevalence of Vitamin D Deficiency Among Population in Iraq: Review Article . International Journal of Medical Science and Clinical Research Studies, 2023, 3(4), 731–734. https://doi.org/10.47191/ijmscrs/v3-i4-29.
  24. Al-Hilali KA. Prevalence of hypovitaminosis D in adult Iraqi people including postmenopausal women. Sci Res J. 2016;4:53-62.
  25. Lokesh KS, Chaya SK, Jayaraj BS, Praveena AS, Krishna M, Madhivanan P, Mahesh PA. Vitamin D deficiency is associated with chronic obstructive pulmonary disease and exacerbation of COPD. Clin Respir J. 2021 Apr;15(4):389-399. doi: 10.1111/crj.13310. Epub 2020 Dec 2. PMID: 33217151; PMCID: PMC8043964.
  26. Niksarlıoğlu EY, Kılıç L, Bilici D, et al. Vitamin D Deficiency and Radiological Findings in Adult Non-Cystic Fibrosis Bronchiectasis. Turk Thorac J. 2020;21(2):87-92. Published 2020 Mar 1. doi:10.5152/TurkThoracJ.2019.18139.
  27. Gilbert CR, Arum SM, Smith CM. Vitamin D deficiency and chronic lung disease. Can Respir J. 2009;16(3):75-80. doi:10.1155/2009/829130.
  28. Ali, H.A., Deraz, et al. Impact of vitamin D status on CF and non-CF bronchiectasis outcomes. Egypt Pediatric Association Gaz 70, 3 (2022). https://doi.org/10.1186/s43054-021-00095-7.
  29. Derbyshire EJ, Calder PC. Bronchiectasis-Could Immunonutrition Have a Role to Play in Future Management?. Front Nutr. 2021;8:652410. Published 2021 Apr 29. doi:10.3389/fnut.2021.652410.
  30. Martineau AR, Thummel KE, Wang Z, et al. differential effects of oral boluses of vitamin D2 vs vitamin D3 on vitamin D metabolism: a randomized controlled trial. J Clin Endocrinol Metab. (2019)104:5831–39. doi: 10.1210/jc.2019-00207.
  31. Ali, H. A., Deraz, et al. (2020). The role of vitamin D3 Therapy in pediatric bronchiectasis severity (CF versus non-CF patients). Open Journal of Pediatrics, 10(3), 521-534.
  32. Bartley J, Garrett J, Camargo CA Jr, et al. Vitamin D3 supplementation in adults with bronchiectasis: A pilot study. Chron Respir Dis. 2018;15(4):384-392. doi:10.1177/1479972318761646.

Volume 10, Issue 2, 2023

 

 

 

 

 

Volume 11, Issue 2, 2024

Downloads: 107

Salman M, Al-Obaidy M. Vitamin D deficiency as a sign of severity in bronchiectasis. Muthanna Medical Journal. 2024; 11(2):124-134.